BLAINJECTIONINJECTABLE
Approved
May 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OPUVIZ (aflibercept-yszy) is a biosimilar fusion protein approved in May 2024 that binds vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) to inhibit neovascularization. It is administered via injection for retinal and ocular vascular diseases. This Samsung Bioepis product represents a follow-on biologic to the reference aflibercept innovator product.
Growth
Early-stage growth asset with moderate competitive pressure (30/100); biosimilar entrant positioning suggests commercial focus on payer conversion and formulary placement rather than patient volume growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
OPUVIZ represents a growth-stage biosimilar launch opportunity with primary career value in commercial execution, payer strategy, and market access rather than clinical development. Role demand reflects biosimilar business model: emphasis on formulary placement, cost-effectiveness communication, and regional managed care navigation over clinical innovation.
Brand Manager
Worked on OPUVIZ at Samsung Bioepis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.